Optimal cut-off age for AJCC staging system in Middle Eastern differentiated thyroid cancer.
[BACKGROUND] Age cut-off of 55 years has been included in the eighth edition of the American Joint Committee on Cancer (AJCC) TNM staging, since it led to better prediction of disease-specific surviva
- p-value p < 0.0001
APA
Parvathareddy SK, Siraj AK, et al. (2025). Optimal cut-off age for AJCC staging system in Middle Eastern differentiated thyroid cancer.. Frontiers in endocrinology, 16, 1494154. https://doi.org/10.3389/fendo.2025.1494154
MLA
Parvathareddy SK, et al.. "Optimal cut-off age for AJCC staging system in Middle Eastern differentiated thyroid cancer.." Frontiers in endocrinology, vol. 16, 2025, pp. 1494154.
PMID
41367912
Abstract
[BACKGROUND] Age cut-off of 55 years has been included in the eighth edition of the American Joint Committee on Cancer (AJCC) TNM staging, since it led to better prediction of disease-specific survival (DSS) of patients with differentiated thyroid cancer (DTC). However, optimal age cut-off in DTC patients from Middle Eastern ethnicity has not been fully explored.
[METHODS] We retrospectively analyzed a large cohort of 1721 adult DTC patients. The optimal age cut-off value was determined using several age cut-offs (between 20 and 85 years) to assess DSS. Harrel's C-Index, Akaike information criterion (AIC) and Bayesian Information Criterion (BIC) were used to assess statistical model performance of the TNM staging system (eighth edition), with different age cut-offs for prediction of DSS.
[RESULTS] The median age of patients at diagnosis was 39.9 years (inter-quartile range 31.0 - 51.7 years) and 75.5% (1299/1721) were female. Median follow up was 9.3 years and 10 years DSS was 97.1%. For DTC overall, an age cut-off of 50 years had the best statistical model performance. On receiver operating characteristic curve analysis, the optimal age cut-off for prediction of DSS was 50.5 years (area under the curve = 0.872, p < 0.0001).
[CONCLUSION] In this large cohort of Middle Eastern DTC patients, an age cut-off of 50 years was more appropriate for TNM staging to achieve better predictability for DSS. Therefore, implementation of different age cut-off for DTC in Middle Eastern patients could improve the predictive value for TNM staging system, allowing for better therapeutic and surveillance approach for these patients.
[METHODS] We retrospectively analyzed a large cohort of 1721 adult DTC patients. The optimal age cut-off value was determined using several age cut-offs (between 20 and 85 years) to assess DSS. Harrel's C-Index, Akaike information criterion (AIC) and Bayesian Information Criterion (BIC) were used to assess statistical model performance of the TNM staging system (eighth edition), with different age cut-offs for prediction of DSS.
[RESULTS] The median age of patients at diagnosis was 39.9 years (inter-quartile range 31.0 - 51.7 years) and 75.5% (1299/1721) were female. Median follow up was 9.3 years and 10 years DSS was 97.1%. For DTC overall, an age cut-off of 50 years had the best statistical model performance. On receiver operating characteristic curve analysis, the optimal age cut-off for prediction of DSS was 50.5 years (area under the curve = 0.872, p < 0.0001).
[CONCLUSION] In this large cohort of Middle Eastern DTC patients, an age cut-off of 50 years was more appropriate for TNM staging to achieve better predictability for DSS. Therefore, implementation of different age cut-off for DTC in Middle Eastern patients could improve the predictive value for TNM staging system, allowing for better therapeutic and surveillance approach for these patients.
MeSH Terms
Humans; Thyroid Neoplasms; Female; Middle Aged; Adult; Male; Neoplasm Staging; Retrospective Studies; Aged; Young Adult; Age Factors; Middle East; Aged, 80 and over; Prognosis; Follow-Up Studies; ROC Curve
같은 제1저자의 인용 많은 논문 (5)
- CD44 and phosphorylated ERK1/2 coexpression predicts distant metastasis in colorectal cancer based on a study of 1137 Saudi patients.
- The Prognostic Impact of Tumor Size and BRAF Mutational Status in Middle Eastern Differentiated Thyroid Cancer.
- No prognostic or molecular disparity between synchronous and metachronous metastases in differentiated thyroid cancer: insight from middle eastern cohort.
- Predicting factors and clinical outcome of biochemical incomplete response in middle eastern differentiated thyroid carcinoma.
- Radioactive iodine refractoriness in Middle Eastern differentiated thyroid cancer: clinical outcome and risk factor analysis.